These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 22055591)

  • 41. [A study on hepatic iron overload in chronic hepatitis C patients].
    Bomfim EA; Pereirade de Oliveira AC; Paraná R; Schinoni MI
    Acta Gastroenterol Latinoam; 2013 Sep; 43(3):212-7. PubMed ID: 24303687
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increased liver mast cells in patients with chronic hepatitis C.
    Koruk ST; Ozardali I; Dincoglu D; Bitiren M
    Indian J Pathol Microbiol; 2011; 54(4):736-40. PubMed ID: 22234100
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association of insulin resistance, viral load, and adipokine levels with liver histology in patients with chronic hepatitis C: an observational, multicenter study in Turkey.
    Aksu HS; Kurtaran B; Onlen Y; Namiduru M; Inkaya AC; Kandemir O; Doran F; Evirgen O; Alpay Y; Tekin SK; Kurekci Y; Unlu B; Midikli D; Taşova Y; Ozdener F; Erdogan S
    Eur J Gastroenterol Hepatol; 2012 Dec; 24(12):1393-9. PubMed ID: 23114743
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevalence of hepatic steatosis in chronic hepatitis B patients and its association with disease severity.
    Lesmana LA; Lesmana CR; Pakasi LS; Krisnuhoni E
    Acta Med Indones; 2012 Jan; 44(1):35-9. PubMed ID: 22451183
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease.
    Svegliati-Baroni G; Bugianesi E; Bouserhal T; Marini F; Ridolfi F; Tarsetti F; Ancarani F; Petrelli E; Peruzzi E; Lo Cascio M; Rizzetto M; Marchesini G; Benedetti A
    Gut; 2007 Sep; 56(9):1296-301. PubMed ID: 17392334
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C.
    Macaluso FS; Maida M; Cammà C; Cabibbo G; Cabibi D; Alduino R; Di Marco V; Craxì A; Petta S
    J Hepatol; 2014 Sep; 61(3):523-9. PubMed ID: 24815874
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Histological features of chronic hepatitis C in haemodialysis patients.
    Sakellariou S; Boletis JN; Sypsa V; Psichogiou M; Tiniakos D; Delladetsima I
    Liver Int; 2014 Jul; 34(6):e56-61. PubMed ID: 25234282
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C.
    Fartoux L; Poujol-Robert A; Guéchot J; Wendum D; Poupon R; Serfaty L
    Gut; 2005 Jul; 54(7):1003-8. PubMed ID: 15951550
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Progression to advanced liver fibrosis in HIV-HCV-coinfected patients and prioritization of new hepatitis C therapies.
    Labarga P; Fernández-Montero JV; López M; Barreiro P; de Mendoza C; Sierra-Enguita R; Treviño A; Soriano V
    Antivir Ther; 2014; 19(8):799-803. PubMed ID: 24964405
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influence of interferon-based therapy on liver fibrosis progression in HIV/HCV coinfected patients: a retrospective repeated liver biopsy analysis.
    Ingiliz P; Valantin MA; Preziosi P; Finzi L; Pais R; Fedchuk L; Dominguez S; Katlama C; Poynard T; Benhamou Y
    J Hepatol; 2012 Jan; 56(1):49-54. PubMed ID: 21781946
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prediction of efficacy of interferon treatment of chronic hepatitis C and occurrence of HCC after interferon treatment by a new classification.
    Kim KI; Sasase N; Taniguchi M; Mita K; Kim SR; Tanaka K; Hayashi Y
    Intervirology; 2005; 48(1):52-8. PubMed ID: 15785090
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum cystatin C: a non-invasive marker of liver fibrosis or of current liver fibrogenesis in chronic hepatitis C? .
    Ladero JM; Cárdenas MC; Ortega L; González-Pino A; Cuenca F; Morales C; Lee-Brunner A
    Ann Hepatol; 2012; 11(5):648-51. PubMed ID: 22947524
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C.
    Bochud PY; Cai T; Overbeck K; Bochud M; Dufour JF; Müllhaupt B; Borovicka J; Heim M; Moradpour D; Cerny A; Malinverni R; Francioli P; Negro F;
    J Hepatol; 2009 Oct; 51(4):655-66. PubMed ID: 19665246
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adiponectin changes in HCV-Genotype 4: relation to liver histology and response to treatment.
    Derbala M; Rizk N; Al-Kaabi S; Amer A; Shebl F; Al Marri A; Aigha I; Alyaesi D; Mohamed H; Aman H; Basem N
    J Viral Hepat; 2009 Oct; 16(10):689-96. PubMed ID: 19486470
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir.
    Younossi ZM; Stepanova M; Afdhal N; Kowdley KV; Zeuzem S; Henry L; Hunt SL; Marcellin P
    J Hepatol; 2015 Aug; 63(2):337-45. PubMed ID: 25795586
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis.
    Castéra L; Hézode C; Roudot-Thoraval F; Lonjon I; Zafrani ES; Pawlotsky JM; Dhumeaux D
    Gut; 2004 Mar; 53(3):420-4. PubMed ID: 14960527
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of steatosis on long-term histological outcome in chronic hepatitis C after antiviral therapy.
    Hung CH; Kuo FY; Wang JH; Lu SN; Hu TH; Chen CH; Lee CM; Eng HL
    Antivir Ther; 2006; 11(4):483-9. PubMed ID: 16856622
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Steatosis and insulin resistance in response to treatment of chronic hepatitis C.
    Negro F
    J Viral Hepat; 2012 Jan; 19 Suppl 1():42-7. PubMed ID: 22233413
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Non-invasive markers and predictors of severity of hepatic fibrosis in HCV patients at Sharkia Governorate, Egypt.
    el-Shorbagy E; Afefy AF; Ibrahem IA; Mangoud AM; Eissa MH; Sabee EI; Mahrous S; Abdel-Monem A; Ismail A; Morsy TA; Etewa S; Nor Edin E; Mostafa Y; Abouel-Magd Y; el-Sedawy M; Ragab H; el-Tokhy H; Hassan MI; Lakouz K; Abdel-Aziz K; el-Hady G; Saber M
    J Egypt Soc Parasitol; 2004 Apr; 34(1 Suppl):459-78. PubMed ID: 15124753
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans.
    Hu KQ; Currie SL; Shen H; Cheung RC; Ho SB; Bini EJ; McCracken JD; Morgan T; Bräu N; Schmidt WN; Jeffers L; Wright TL;
    Dig Dis Sci; 2007 Feb; 52(2):570-8. PubMed ID: 17226072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.